Published by Josh White on 24th March 2025
(Sharecast News) - GSK said on Monday that the European Medicines Agency has accepted its application to expand the use of 'Nucala', or mepolizumab, to include patients with chronic obstructive pulmonary disease (COPD) who have an eosinophilic phenotype.
URL: http://www.digitallook.com/dl/news/story/34961850/...